Indeed, we predicted C2 to be significantly more likely to respond to anti-PD-1 and anti-CTLA4 treatment when we compared expression profiles of C1 and C2 with those of melanoma patients who responded to immunotherapy (Figure 6D; Roh et al., 2017). The gene discussed is CTLA4; the disease is melanoma.